Pulmonary hypertension (PH) is a progressive disease that if left untreated, has very high morbidity and mortality due to right-sided heart failure. Pulmonary hypertension falls into five separate World Health Organization (WHO) groups based on the etiology, which has important ramifications for subsequent management. Group 1 is pulmonary arterial hypertension (PAH). PAH can be due to genetic causes, connective tissue diseases, HIV, schistosomiasis, portal hypertension or drugs and toxins. Group 2 is PH due to left heart disease. Group 3 is PH due to chronic lung disease and/or hypoxemia. Group 4 is PH due to pulmonary artery obstruction, most commonly from venous thromboembolism (VTE). Group 5 is PH due to multifactorial mechanisms. The clinician can diagnose PH via a right heart catheterization (RHC) showing a mean pulmonary artery pressure (mPAP) of over 25mm Hg or a pulmonary vascular resistance (PVR) greater than 3 Woods units. A normal pulmonary artery wedge pressure of under 15 mmHg is required to exclude group 2 PH. Currently, there are several pulmonary vasodilator agents with approval for the medical management of PAH, including endothelin receptors antagonists (ERA), phosphodiesterase-5 (PDE-5) inhibitors, and prostanoids.
Treprostinil is a synthetic analog of prostacyclin approved for the treatment of Group 1 or PAH. It is a direct vasodilator of both pulmonary and systemic vascular beds; thereby reducing pulmonary artery pressure and improving systemic oxygenation.
The infusion form is for patients with PAH (WHO Group I) with New York Heart Association (NYHA) class II-IV. The inhaled form is used to treat PAH in patients with NYHA class III. The oral form is used to treat PAH in patients with NYHA class II-III.
Studies have also shown that in patients with severe chronic thromboembolic pulmonary hypertension (CTEPH) or WHO Group 4 PH, exercise capacity can improve with subcutaneous Treprostinil.
The TRIUMPH-I trial (Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) demonstrated that patients who were symptomatic despite dual treatment with bosentan (ERA) and sildenafil (PDE-5 inhibitor) improved clinically after the addition of treprostinil with improved quality of life and exercise capacity measured by an increased 6 minute walk distance (6MWD).
This drug is available in multiple forms, inhaled, oral, and intravenous (IV). Treprostinil received approval from the Food and Drug Administration (FDA) in 2009 for the inhaled form, 2013 for the oral form and 2017 for the infusion form.
Treprostinil is a chemically stable prostacyclin analog. Its principal pharmacologic action is direct vasodilation, which causes reduction of pulmonary and systemic arterial pressure, reducing right and left ventricular afterload; therefore improves the cardiac output. It also has an antiplatelet effect.
Treprostinil is available in three formulations: intravenous or continuous subcutaneous, oral and inhaled. Each formulation is beneficial to patients with PAH. Different routes have different adverse effects, and the knowledge of these effects will facilitate transitioning between these formulations. For example, patients receiving the infusion form experienced infusion site pain, patients receiving the oral form experienced abdominal discomfort, which this activity will discuss in more details in the “Adverse Effects” section. The subcutaneous (SQ) route is preferred as the drug will rapidly and completely absorb, and is administered via an infusion pump. If the patient is not tolerant of the SQ infusion route, they can change to IV infusion. In this case, the solution must be diluted and administered through an indwelling central catheter, which can increase the risk of sepsis and bacteremia. Patients receiving inhaled treprostinil should be able to care for the system and the accessories. They should also have back up devices to avoid interruption of the treatment.
Treprostinil should not be mixed with any other medications. The oral form can be administered with food and should not be crushed or chewed. The absorption of the oral treprostinil increases when administered following a high-fat, high-calorie meal. Dosing requires adjustment in hepatic impairment due to decreased hepatic clearance and increased systemic exposure.
The metabolism of this medication is hepatic via CYP2C8 to form several inactive metabolites, which then get excreted through urine and feces.
SQ absorption is almost immediate, whereas orally the time to peak is 4 to 6 hours. The half-life is 4 hours.
Local adverse effects are the most common side effects related to either the SQ or inhaled routes of administration:
Systemic adverse effect:
There are no contraindications to administering the SQ, IV, or inhaled route of medication. However, the dosage requires adjustment in mild, moderate, and severe hepatic dysfunction. Contraindications to the oral form of treprostinil include severe hepatic dysfunction (Child-Pugh class C).
Treprostinil dosing must be carefully titrated slowly in an individualized manner, monitoring for symptom improvement with minimal adverse reactions at the current dosage.
Since treprostinil metabolism is via the liver, in patients with hepatic impairment; infusion and oral form of this medication can be initiated at a lower dose and titrated slowly..
Researchers have not studied the safety of the inhaled form in patients with underlying pulmonary disease.
Researchers did encounter treprostinil overdose during the trials which presented with signs and symptoms of vasodilatation such as flushing, hypotension, and headache. It can also be a result of pump dysfunction, accidental bolus administration, or prescribing the wrong dose. These symptoms are self-limited and will be resolved by temporarily discontinuing the medication or reducing the dosage.
In patients with PAH (WHO group 1), treprostinil has been shown to improve the quality of life and the exercise capacity of patients who receive treatment. The effects of this drug have been the subject of study in multiple randomized controlled trials (RCT).
However, patients with PAH will benefit from an interprofessional team approach to determine the optimal management. Patients with pulmonary hypertension, when treated with treprostinil, need close monitoring as adverse effects are common. Nursing will be at the front lines in this aspect since they have the first contact with the patient at each visit. They must report any suspected therapy failure or adverse effects to the prescribing physician immediately. Also, not all patients have the same response to the drug. Patients need to receive education from the pharmacist that medication compliance is critical for optimal response. Pharmacists must also perform medication reconciliation and verify dosing parameters. Only through interprofessional collaboration as outlined above, can the patient achieve the best available results form treprostinil therapy. [Level V]
However, the outcomes for most patients with pulmonary hypertension are guarded; to date, medications do improve the quality of life but offer no cure. The life expectancy of these patients is also markedly reduced.
|||Montani D,Günther S,Dorfmüller P,Perros F,Girerd B,Garcia G,Jaïs X,Savale L,Artaud-Macari E,Price LC,Humbert M,Simonneau G,Sitbon O, Pulmonary arterial hypertension. Orphanet journal of rare diseases. 2013 Jul 6; [PubMed PMID: 23829793]|
|||Channick RN,Voswinckel R,Rubin LJ, Inhaled treprostinil: a therapeutic review. Drug design, development and therapy. 2012; [PubMed PMID: 22291467]|
|||McLaughlin VV,Benza RL,Rubin LJ,Channick RN,Voswinckel R,Tapson VF,Robbins IM,Olschewski H,Rubenfire M,Seeger W, Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology. 2010 May 4; [PubMed PMID: 20430262]|
|||Chattaraj SC, Treprostinil sodium Pharmacia. Current opinion in investigational drugs (London, England : 2000). 2002 Apr; [PubMed PMID: 12090728]|
|||Taichman DB,Ornelas J,Chung L,Klinger JR,Lewis S,Mandel J,Palevsky HI,Rich S,Sood N,Rosenzweig EB,Trow TK,Yung R,Elliott CG,Badesch DB, Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug; [PubMed PMID: 24937180]|
|||Horn EM,Barst RJ, Treprostinil therapy for pulmonary artery hypertension. Expert opinion on investigational drugs. 2002 Nov; [PubMed PMID: 12437507]|
|||Skoro-Sajer N,Lang I,Naeije R, Treprostinil for pulmonary hypertension. Vascular health and risk management. 2008; [PubMed PMID: 18827901]|
|||Gleason JB,Dolan J,Piran P,Rahaghi FF, The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension. Case reports in pulmonology. 2015; [PubMed PMID: 26457220]|
|||Walsh M,Hanna BD, A pediatric case study of treprostinil overdose. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2009 Mar; [PubMed PMID: 19285625]|
|||Hiremath J,Thanikachalam S,Parikh K,Shanmugasundaram S,Bangera S,Shapiro L,Pott GB,Vnencak-Jones CL,Arneson C,Wade M,White RJ, Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2010 Feb; [PubMed PMID: 20022264]|